X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs J.B.CHEMICALS - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE J.B.CHEMICALS CADILA HEALTHCARE/
J.B.CHEMICALS
 
P/E (TTM) x 32.4 14.9 216.6% View Chart
P/BV x 6.0 2.4 254.6% View Chart
Dividend Yield % 0.8 0.2 476.8%  

Financials

 CADILA HEALTHCARE   J.B.CHEMICALS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
J.B.CHEMICALS
Mar-16
CADILA HEALTHCARE/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs460318 144.6%   
Low Rs305200 152.9%   
Sales per share (Unadj.) Rs92.1148.0 62.2%  
Earnings per share (Unadj.) Rs14.819.1 77.6%  
Cash flow per share (Unadj.) Rs18.523.9 77.2%  
Dividends per share (Unadj.) Rs3.200.50 640.0%  
Dividend yield (eoy) %0.80.2 433.0%  
Book value per share (Unadj.) Rs68.0128.9 52.7%  
Shares outstanding (eoy) m1,023.7484.82 1,207.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.7 237.4%   
Avg P/E ratio x25.813.6 190.4%  
P/CF ratio (eoy) x20.710.8 191.5%  
Price / Book Value ratio x5.62.0 280.3%  
Dividend payout %21.62.6 824.4%   
Avg Mkt Cap Rs m391,58121,951 1,783.9%   
No. of employees `00016.92.7 616.5%   
Total wages/salary Rs m15,0021,841 814.8%   
Avg. sales/employee Rs Th5,594.54,590.9 121.9%   
Avg. wages/employee Rs Th890.1673.4 132.2%   
Avg. net profit/employee Rs Th899.9592.1 152.0%   
INCOME DATA
Net Sales Rs m94,29512,551 751.3%  
Other income Rs m1,286542 237.4%   
Total revenues Rs m95,58113,093 730.0%   
Gross profit Rs m19,0362,055 926.5%  
Depreciation Rs m3,750412 909.3%   
Interest Rs m45096 470.2%   
Profit before tax Rs m16,1222,088 772.1%   
Minority Interest Rs m3380 -84,500.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,289469 274.8%   
Profit after tax Rs m15,1681,619 937.0%  
Gross profit margin %20.216.4 123.3%  
Effective tax rate %8.022.5 35.6%   
Net profit margin %16.112.9 124.7%  
BALANCE SHEET DATA
Current assets Rs m60,2237,778 774.3%   
Current liabilities Rs m53,0584,358 1,217.5%   
Net working cap to sales %7.627.2 27.9%  
Current ratio x1.11.8 63.6%  
Inventory Days Days7055 127.7%  
Debtors Days Days8880 110.2%  
Net fixed assets Rs m72,9845,713 1,277.6%   
Share capital Rs m1,024170 603.8%   
"Free" reserves Rs m68,57610,547 650.2%   
Net worth Rs m69,60010,937 636.4%   
Long term debt Rs m24,6840-   
Total assets Rs m152,20715,574 977.3%  
Interest coverage x36.822.8 161.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.60.8 76.9%   
Return on assets %10.311.0 93.2%  
Return on equity %21.814.8 147.3%  
Return on capital %17.920.0 89.8%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m21,2806,169 345.0%   
Fx outflow Rs m10,8741,285 846.1%   
Net fx Rs m10,4064,884 213.1%   
CASH FLOW
From Operations Rs m13,4951,397 966.2%  
From Investments Rs m-29,103-320 9,086.2%  
From Financial Activity Rs m23,158-1,196 -1,936.6%  
Net Cashflow Rs m7,556-102 -7,386.1%  

Share Holding

Indian Promoters % 74.8 55.4 135.0%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 8.3 3.4 244.8%  
FIIs % 5.9 3.9 151.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 37.0 29.7%  
Shareholders   44,069 30,437 144.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  ELDER PHARMA  SUVEN LIFE  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 20, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - PFIZER COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS